The FDA Approves Gilead Science's Remdesivir for All Stages of Kidney Disease including Dialysis, and Removes Precaution to Check for Bleeding and Liver Damage Before and During Use
Gilead Science's press release has two contact emails at the bottom: one for investors: investor_relations@gilead.com and the other for media inquiries: public_affairs@gilead.com
In an incredible and in-your-face move, on July 14, 2023, the FDA quietly approved Gilead’s Veklury (AKA remdesivir or RUN DEATH IS NEAR) for Covid-19 patients who have severe renal impairment. It is now approved for patients who are either 1) hospitalized or 2) not hospitalized but at high risk for COVID sequelae or death; and 3) does not require labs to check for bleeding or liver damage prior to or during use.
Now, even patients with end-stage kidney failure on dialysis can even get remdesivir, according to Gilead’s July 14, 2023 announcement.
Thank you for reading my writings, and for being the awesome person that you are!
What is Remdesivir?
If you have never heard of Remdesivir (also known as Veklury, so don’t be fooled by a hospital that tries to tell you it’s a different drug; every drug has a trade name and a generic name), this is an IV antiviral drug that was FDA approved for use in hospitalized COVID patients - and it causes kidney and liver failure, killing patients via “hospital protocols” that reimburse the hospital with government money every time it is used.
In an African trial that Fauci helped author, Remdesivir not only failed on Ebola virus, but it caused more deaths than the control drug and forced an early end to the study. Knowing this, Fauci slated it for approval and constantly referenced its use for COVID. As if it was going to help.
The topic of avoiding remdesivir has been on our Medical Directives updates, Twitter Spaces, and more. Literally every medical freedom doctor and advocate has been telling everyone not only to avoid remdesivir, but to avoid hospitals - so they don’t force it on you. THIS is why you need a Medical Directive.
You can review drug data, pharmaceutical statements, and press releases by going here, here, and here, or read on as a paid subscriber and see everything at once.
Here is the Press Release:
It includes WHAT I REALLY THINK
Keep reading with a 7-day free trial
Subscribe to The Rebel Patient™ to keep reading this post and get 7 days of free access to the full post archives.